Mepolizumab ‘super responders’ seen in severe eosinophilic asthma
By Michael Woodhead
24 Mar 2020
Real world patients with severe eosinophilic asthma show the same good outcomes with mepolizumab as seen in clinical trials – with a particular group of ‘super responders’ with a T2 phenotype, an Australian study has shown. A registry based study found that the anti-IL5 treatment reduced severe exacerbations, hospitalisations and improved asthma symptoms, quality of ...